Two anti-VEGFs demonstrate no visual acuity difference at 2 years, CATT author says

SEATTLE — Despite what many have said, the Comparison of Age-Related Macular Degeneration Treatment Trials showed ranibizumab and bevacizumab are equivalent for visual acuity, according to an expert speaking here. “We are talking about a 0.5 D difference,” Daniel F. Martin, MD, said regarding visual acuity results in the CATT. “People see it the way they want to see it, but one line is really trivial. This is noise. There is no statistically significant difference at 2 years.”

Full Story →